Shots:
- Contineum Therapeutics reported the initiation of patient dosing in exploratory P-Ib study of PIPE-791 for chronic pain associated with two separate indications, osteoarthritis (OA) and low back pain (LBP)
- The company expects to enroll approx. 40 pts. for a treatment duration of 28 days and anticipates topline data in early 2026
- PIPE-791 is a small molecule antagonist of the lysophosphatidic acid 1 receptor (LPA1R) and can penetrate the brain
Ref: Contineum Therapeutics | Image: Contineum Therapeutics
Related News:- Daiichi Sankyo Reports Interim Data of P-III (DESTINY-Gastric04) Study Evaluating Enhertu in HER2+ Metastatic Gastric Cancer Patients
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
